Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Depreciation and Depletion (2020 - 2025)

Historic Depreciation and Depletion for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $1.3 million.

  • 4D Molecular Therapeutics' Depreciation and Depletion rose 833.33% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 408.16%. This contributed to the annual value of $4.8 million for FY2024, which is 909.09% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Depreciation and Depletion is $1.3 million, which was up 833.33% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Depreciation and Depletion ranged from a high of $1.3 million in Q4 2023 and a low of $400000.0 during Q1 2021
  • Its 5-year average for Depreciation and Depletion is $905263.2, with a median of $1.1 million in 2023.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Depreciation and Depletion skyrocketed by 15000.0% in 2022, and later plummeted by 769.23% in 2024.
  • 4D Molecular Therapeutics' Depreciation and Depletion (Quarter) stood at $400000.0 in 2021, then surged by 150.0% to $1.0 million in 2022, then rose by 30.0% to $1.3 million in 2023, then dropped by 7.69% to $1.2 million in 2024, then rose by 8.33% to $1.3 million in 2025.
  • Its Depreciation and Depletion stands at $1.3 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.3 million for Q1 2025.